The NHS is one of the world’s most ambitious public health systems, but it faces mounting pressures from an ageing population, chronic illnesses, and limited public funding.
Startups are stepping up to tackle healthcare’s tough challenges, giving clinicians better tools and patients more control.
From blood tests that let patients monitor their health at home to AI-powered mental health platforms that speed up access to care, here are 10 UK startups that are modifying how care is delivered, tracked, and experienced.
Entia
Founder/s: Toby Basey-Fisher
Founded year: 2014
Total funding: $37M
London-based Entia, founded in 2014 by Toby Basey-Fisher, develops a compact, connected home device for finger-prick blood testing called Liberty. It analyses blood samples in minutes and securely sconcludes the results to clinicians.
Rather than a trip to a hospital or health centre, the Liberty device supports improve patients’ quality of life by building healthcare more convenient, timely, and private.
Backed by Parkwalk, Entia secured a £16M Series A round in 2023. It’s an example of how private companies can support meet the government’s 10 Year Plan for Health by shifting healthcare out of hospitals and into homes, where patients feel more comfortable.
Psyomics
Founder/s: Prof. Sabine Bahn and Dan Cowell
Founded year: 2015
Total funding: $16.6M
Psyomics, a University of Cambridge spin-out founded in 2015 by Prof. Sabine Bahn and Dan Cowell, had developed a platform to assess patients’ mental health journeys and identify personalised treatment pathways.
Clinical questionnaires are an important but repetitive and time-consuming part of mental health treatment. Psyomics’s platform, called beseen, utilizes clinically validated questionnaires and machine learning to assess a patient’s mental health journey. The idea is to allow clinicians to concentrate on their patients while also supporting to identify more effective personalised treatment pathways.
With a £3.5M investment from Parkwalk, Psyomics demonstrates that even the most personal mental health treatment can be supported by AI. With this approach to accelerating the patient journey, Psyomics are supporting to reduce therapy waiting lists.
Huma
Founder/s: Dan Vahdat
Founded year: 2011
Total funding: $16.6M
Huma, founded in 2011 in London by Dan Vahdat, has built a cloud platform that collects, consolidates, and securely shares health data from medical devices and wearables for remote patient monitoring.
The technology means that concerns or warning signals can be spotted ahead of time, in patients’ homes.
More than 3,000 hospitals worldwide, including many in the NHS, utilize Huma’s platform Its value came to the fore during the COVID pandemic, when home monitoring supported reduce infection risk and keep beds available for those most in necessary.
In 2024, Huma secured $80M in a Series D round, bringing total funding to over $300M. The investment advances its AI-driven digital health platform, shifting care toward personalised, home-based models.
Peppy
Founder/s: Dr. Mridula Pore, Max Landry, and Evan Harri
Founded year: 2018
Total funding: $57.7M
Peppy, founded in 2018 by Dr Mridula Pore, Max Landry, and Evan Harri, delivers employer-sponsored digital health services specialising in fertility, menopautilize, men’s health, and family planning.
The platform connects employees directly with healthcare specialists, providing access to secure, confidential, expert support, while their employers benefit from healthier and happier staff.
The London headquartered company is Europe’s largest gconcludeer-based healthcare benefits platform, it claims, and secured $45M in 2023 to support it expand into the US market.
Ieso Digital Health
Founder/s: David Schrumm
Founded year: 2000
Total funding: $78.1M
Ieso Digital Health, founded in 2000 in Cambridge by David Schrumm, delivers online text-based cognitive-behavioural therapy (CBT) to address geographic barriers and therapist shortages in mental healthcare.
Patients access fully qualified therapists remotely for convenient, private sessions, while structured CBT generates anonymised data that is utilized to inform treatment pathways at a larger scale. It has supported over 145,000 NHS patients, as one of the UK’s leading digital mental health platforms.
Last year, Ieso was acquired by Swedish healthtech company Mindler, enhancing its scale and NHS integration to enable broader access to therapy.
Numan
Founder/s: Tim Robinson (CEO) and Charlie Kerr
Founded year: 2018
Total funding: $102M
Numan, founded in 2018 in London by Tim Robinson and Charlie Kerr, operates a direct-to-consumer telehealth platform tackling men’s reluctance to seek medical support. It offers online consultations, at-home diagnostics, and discreet delivery for sensitive conditions like hair loss, ED, and STIs.
With oversight from GMC-registered clinicians and pharmacies, it reduces stigma, encourages early intervention, and promotes preventive care. The model has driven rapid adoption amid rising demand for convenient men’s health services.
Recently, Numan secured £60M to redefine preventive healthcare and enter new markets, and doubled revenue while scaling operations across Europe.
Phlo
Founder/s: Nadeem Sarwar
Founded year: 2021
Total funding: $31.6M
Phlo, founded in 2021 in Glasgow by Nadeem Sarwar, modernises NHS prescription fulfilment. It is a fully approved digital pharmacy that integrates with GP surgeries for seamless electronic processing and free 48-hour nationwide delivery.
The company also combines clinical oversight with modern logistics by enabling patients to track prescriptions on an app.
Recently, Phlo has expanded across the UK, after raising £9M to scale same-day delivery and national coverage.
Evaro
Founder/s: Dr Thuria Wenbar and Dr Oskar Wenbar
Founded year: 2018
Total funding: $52.1M
Evaro, founded in 2018 in Norwich by NHS professionals Dr Thuria Wenbar and Dr Oskar Wenbar, provides a white-label, fully regulated digital pharmacy and clinical platform for healthcare services.
The company enables other brands to offer care, including consultations, prescriptions, diagnostics, and aftercare, via an API that can be deployed within two weeks.
It handles compliance (NHS, CQC, GPhC approvals), supports over 80 conditions across health and acute care, and saves the NHS £11M by reducing visits. It has assisted over two million patients.
In January,, Evaro raised $25M in a Series A round led by AlbionVC, with Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI also participating. Funds tarobtain longevity, advanced diagnostics, complex services, and partnerships with brands/healthcare providers, and employers.
Causaly
Founder/s: Yiannis Kiachopoulos (CEO) and Artur Saudabayev (CTO)
Founded year: 2018
Total funding:
Causaly, founded by Yiannis Kiachopoulos and Artur Saudabayev, has created an AI platform that accelerates biomedical research by analysing millions of publications to reveal hidden insights into disease biology, biomarkers, and drug tarobtains.
By combining knowledge graphs with generative AI, the company claims to deliver 10x productivity gains for pharma researchers, from tarobtain identification to preclinical validation. The platform transforms “search, read, synthesise” workflows into direct question-answering, powering novel discoveries and higher success rates. It works with 12 of the top 20 pharma companies, including Gilead, Novartis, and Regeneron.
In 2023, Causaly raised $60M in a Series B round led by ICONIQ Growth, with participation from Index Ventures, Marathon, and EBRD, bringing their total funding to over $93 million. They recently added another £46 million.
Healthera
Founder/s: Quintus Liu (CEO), Martin Hao, and Jin Dai
Founded year: 2015
Total funding: $7.7M
Healthera, founded in 2015 by University of Cambridge alumni Quintus Liu, Martin Hao, and Jin Dai, is a digital pharmacy platform that connects patients to over 1,700 pharmacies and NHS GPs for prescription management, tracking, medication reminders, and clinical services via an app.
Patients order repeats, monitor intake, and access services digitally, while pharmacies utilize white-label apps to boost engagement and loyalty, processing around 5M prescriptions in 2024. Its partners outperformed the market by 10%, per the company, which claims to digitise 98% of manual interactions between patients, pharmacists, and GPs.
In April 2025, Healthera secured a £2M strategic investment, boosting its Series A to £5.6M, led by Committed Capital. Cambridge Enterprise, NHS England, and Innovate UK also participated. Funds were earmarked for growth and North American expansion, with the ultimate goal of future-proofing community pharmacies.
This article is part of Tech Funding News’ editorial partnership with Parkwalk, a leading UK investment fund focutilized on university spinouts and deep tech innovation.
Leave a Reply